查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356795

自體免疫肝炎診斷與治療市場報告：至2030年的趨勢趨勢、預測與競爭分析

Autoimmune Hepatitis Diagnosis and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

自體免疫肝炎診斷和治療的趨勢和預測

至2030年，全球自體免疫肝炎診斷和治療市場預計將達到3億美元，2024年至2030年年複合成長率為5.3%。該市場的主要促進因素是自體免疫肝炎盛行率的增加，醫療基礎設施投資的增加，診斷工具的改進和技術進步。全球自體免疫肝炎診斷和治療市場的未來對於醫院/診所、診斷中心和研究機構市場來說是充滿希望的。

自體免疫肝炎診斷與治療市場洞察

Lucintel 預測，由於對疾病早期檢測的需求不斷增加、臨床應用不斷擴大以及患有慢性病的老年人口迅速成長，影像檢查將在預測期內實現最高成長。

在這個市場中，醫院和診所仍將是最大的區隔。

由於酒精消費量增加、非法藥物使用、肝病患者迅速增加以及政府機構和私人組織提高意識活動，北美在預測期內可能仍然是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個細分市場將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
  • Q.1.1.過去年度發生了哪些類型的併購，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球自體免疫肝炎診斷與治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球自體免疫肝炎診斷及治療市場趨勢（2018-2023）及預測（2024-2030）
  • 全球自體免疫肝炎診斷與治療市場（依類型）
    • I型
    • II型
    • 變異型AIH
  • 全球自體免疫肝炎診斷與治療市場（按診斷）
    • 驗血
    • 影像檢查
    • 切片檢查
  • 按治療分類的全球自體免疫肝炎診斷與治療市場
    • 藥品
    • 皮質類固醇
    • 免疫系統抑制劑
    • 肝臟移植
  • 全球自體免疫肝炎診斷與治療市場（依最終用途產業）
    • 醫院和診所
    • 診斷中心
    • 調查機構
    • 其他

第4章 2018-2030年市場趨勢及預測分析（依地區）

  • 全球自體免疫肝炎診斷與治療市場（依地區）
  • 北美自體免疫肝炎診斷與治療市場
  • 歐洲自體免疫肝炎診斷與治療市場
  • 亞太地區自體免疫肝炎診斷與治療市場
  • 其他地區自體免疫肝炎診斷與治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球自體免疫肝炎診斷與治療市場成長機會（依類型）
    • 全球自體免疫肝炎診斷與治療市場成長機會（依診斷）
    • 全球自體免疫肝炎診斷與治療市場成長機會（依治療）
    • 全球自體免疫肝炎診斷和治療市場成長機會（依最終用途行業）
    • 全球自體免疫肝炎診斷與治療市場成長機會（依地區）
  • 全球自體免疫肝炎診斷與治療市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球自體免疫肝炎診斷和治療市場的能力
    • 全球自體免疫肝炎診斷與治療市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Abbott Laboratories
  • AbbVie
  • Arihantanam Life Care
  • AstraZeneca PLC
  • Bayer
  • Biocon
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • Cipla
簡介目錄

Autoimmune Hepatitis Diagnosis and Treatment Trends and Forecast

The future of the global autoimmune hepatitis diagnosis and treatment market looks promising with opportunities in the hospital & clinic, diagnostic centre, and research institution markets. The global autoimmune hepatitis diagnosis and treatment market is expected to reach an estimated $0.3 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are increase in the prevalence of autoimmune hepatitis, rise investment for healthcare infrastructure ,and improved diagnostic tools and technological advancements.

A more than 150-page report is developed to help in your business decisions.

Autoimmune Hepatitis Diagnosis and Treatment by Segment

The study includes a forecast for the global autoimmune hepatitis diagnosis and treatment by type, diagnosis, treatment, end use industry, and region.

Autoimmune Hepatitis Diagnosis and Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Type-I
  • Type-II
  • Variant AIH

Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Test
  • Imaging Test
  • Liver Biopsy

Autoimmune Hepatitis Diagnosis and Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Corticosteroids
  • Immune System Suppressors
  • Liver Transplant

Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Diagnostic Centre
  • Research Institutions
  • Others

Autoimmune Hepatitis Diagnosis and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Autoimmune Hepatitis Diagnosis and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies autoimmune hepatitis diagnosis and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the autoimmune hepatitis diagnosis and treatment companies profiled in this report include-

  • Abbott Laboratories
  • Abbvie
  • Arihantanam Life Care
  • Astrazeneca Plc
  • Bayer
  • Biocon
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • Cipla

Autoimmune Hepatitis Diagnosis and Treatment Market Insights

Lucintel forecasts that imaging test is expected to witness highest growth over the forecast period due to the increasing requirement for early disease detection, an expanding range of clinical applications, and the rapidly growing elderly population afflicted by chronic ailments.

Within this market, hospitals & clinics will remain the largest segment.

North America will remain the largest region over the forecast period due to heightened alcohol consumption, illicit drug use, a surge in liver disease cases, and growing awareness campaigns conducted by both governmental and private organizations.

Features of the Global Autoimmune Hepatitis Diagnosis and Treatment Market

Market Size Estimates: Autoimmune hepatitis diagnosis and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Autoimmune hepatitis diagnosis and treatment market by various segments, such as by type, diagnosis, treatment, end use industry and region in terms of($B).

Regional Analysis: Autoimmune hepatitis diagnosis and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, diagnosis, treatments, end use industries, and region.s for the autoimmune hepatitis diagnosis and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the autoimmune hepatitis diagnosis and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the autoimmune hepatitis diagnosis and treatment market size?

Answer: The global autoimmune hepatitis diagnosis and treatment market is expected to reach an estimated $0.3 billion by 2030.

Q.2. What is the growth forecast for autoimmune hepatitis diagnosis and treatment market?

Answer: The global autoimmune hepatitis diagnosis and treatment market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the autoimmune hepatitis diagnosis and treatment market?

Answer: The major drivers for this market are increase in the prevalence of autoimmune hepatitis, rise investment for healthcare infrastructure, and improved diagnostic tools and technological advancements.

Q.4. What are the major segments for autoimmune hepatitis diagnosis and treatment market?

Answer: The future of the autoimmune hepatitis diagnosis and treatment market looks promising with opportunities in the hospital & clinic, diagnostic centre, and research institution markets.

Q.5. Who are the key Autoimmune Hepatitis Diagnosis and Treatment Market companies?

Answer: Some of the key autoimmune hepatitis diagnosis and treatment companies are as follows:

  • Abbott Laboratories
  • AbbVie
  • Arihantanam Life Care
  • AstraZeneca PLC
  • Bayer
  • Biocon
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • Cipla

Q.6. Which autoimmune hepatitis diagnosis and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that imaging test is expected to witness highest growth over the forecast period due to the increasing requirement for early disease detection, an expanding range of clinical applications, and the rapidly growing elderly population afflicted by chronic ailments.

Q.7. In autoimmune hepatitis diagnosis and treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to heightened alcohol consumption, illicit drug use, a surge in liver disease cases, and growing awareness campaigns conducted by both governmental and private organizations.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the autoimmune hepatitis diagnosis and treatment market by type (type-I, type-II, and variant AIH), diagnosis (blood test, imaging test, and liver biopsy), treatment (medication, corticosteroids, immune system suppressors, and liver transplant), end use industry (hospitals & clinics, diagnostic centre, research institutions, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.1. 1. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Autoimmune Hepatitis Diagnosis and Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Autoimmune Hepatitis Diagnosis and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Type
    • 3.3.1: Type-I
    • 3.3.2: Type-II
    • 3.3.3: Variant AIH
  • 3.4: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis
    • 3.4.1: Blood Test
    • 3.4.2: Imaging Test
    • 3.4.3: Liver Biopsy
  • 3.5: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Treatment
    • 3.5.1: Medication
    • 3.5.2: Corticosteroids
    • 3.5.3: Immune System Suppressors
    • 3.5.4: Liver Transplant
  • 3.6: Global Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Diagnostic Centre
    • 3.6.3: Research Institutions
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Region
  • 4.2: North American Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.2.1: North American Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.2.2: North American Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others
  • 4.3: European Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.3.1: European Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.3.2: European Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others
  • 4.4: APAC Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.4.1: APAC Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.4.2: APAC Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others
  • 4.5: ROW Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.5.1: ROW Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.5.2: ROW Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Treatment
    • 6.1.4: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry
    • 6.1.5: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Region
  • 6.2: Emerging Trends in the Global Autoimmune Hepatitis Diagnosis and Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Autoimmune Hepatitis Diagnosis and Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Autoimmune Hepatitis Diagnosis and Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott Laboratories
  • 7.2: AbbVie
  • 7.3: Arihantanam Life Care
  • 7.4: AstraZeneca PLC
  • 7.5: Bayer
  • 7.6: Biocon
  • 7.7: Bio-Rad Laboratories
  • 7.8: Bristol-Myers Squibb
  • 7.9: Cipla